- Clinical-stage regenerative company Sernova (SVA) is staging a rapid share price rally, as it prepares to release key findings from its recent FDA cleared study
- Sernova’s clinical trials are assessing the safety and tolerability of islet transplant into diabetic subjects with hypoglycemia unawareness
- Dr. Piotr Witkowski, Director of Pancreatic and Islet Transplant Program at the University of Chicago is scheduled to discuss findings
- Sernova’s hopes to conclude that the study results in a reduction or elimination of insulin injections for patients
- Sernova (SVA) is currently up 12.90 per cent and is trading at C$0.70 per share
Clinical-stage regenerative company Sernova (SVA) is staging a rapid share price rally, as it prepares to release key findings from a recent study.
Sernova (SVA) is a Canadian clinical-stage regenerative company in search of discovering a long-term treatment for replacing therapeutic cells such as pancreatic islets to control blood sugar levels naturally.
The company shares have been staging a rapid rally since the beginning of December, so far jumping more than 140 per cent.
Amid the share price rally, the company’s key Phase I/II clinical trial, “A Safety, Tolerability and Efficacy Study of Sernova’s Cell Pouch for Clinical Islet Transplantation”, is now set to be discussed on January 15, 2021.
More than 600 transplant professionals are to be in attendance for the Oral Abstract Session II.
Dr. Piotr Witkowski, Director of the Pancreatic and Islet Transplant Program at the University of Chicago is set to present his findings. This presentation will be delivered at the American Society of Transplant Surgeons 21st Annual State of the Art Winter Symposium.
Due to COVID, sessions will be held virtually so all can attend.
Started in 1989, Sernova was once called Pheromone Sciences before changing its name in 2006. Then Chairman, Dr. William Cochrane, said it was a better fit.
“The new name fits better with projects such as our current development of a potential breakthrough treatment for diabetes,” he said.
Fast forward to current day, and Sernova is set to discuss phase I/II of its FDA cleared clinical study which had two main objectives. Firstly, to show the safety and admissibility of the islet transplantation into the Cell Pouch for the treatment of TID.
Secondly, to determine the islet release criteria that can correctly illustrate the islet product “and are predictive of clinical transplant outcomes into the Cell Pouch, which will be demonstrated through defined efficacy measures”.
Patients who are part of Sernova’s clinical trial are incapable of creating C-peptide, a biomarker for insulin produced by islet cells.
These patients are implanted with Cell Pouches and eventually stabilized on immunosuppression. After a period of time, a sentinel pouch is removed for an early assessment of the transplant.
Follow-ups take place as an additional safety measure for up to six months. After a year, they will again be followed up with to assess longer-term safety and efficacy.
The end goal for Sernova’s clinical trial is to come up with a “functional cure” to improve the lives of people dealing with a chronic disease such as diabetes.
Sernova (SVA) is currently up 12.90 per cent and is trading at C$0.70 per share as of 4:00pm EST.
